Leveraging preclinical study designs to close gaps in vaccine development for perinatal pathogens.

Publication Year: 2023

DOI:
10.1084/jem.20230184

PMCID:
PMC10250551

PMID:
37289272

Journal Information

Full Title: J Exp Med

Abbreviation: J Exp Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosures: S.R. Permar serves as a consultant to Merck, Pfizer, Moderna, Dynavax, GSK, and Hoopika CMV vaccine programs and leads sponsored vaccine programs with Moderna and Merck. No other disclosures were reported."

Evidence found in paper:

"This work was supported in part by P01AI129859 from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health to S.R. Permar."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025